In particular, the consistent findings of the highly pleiotropic oncosuppressive role of RNASET2 in ovarian cancer (acting at both cell-autonomous and noncell-autonomous levels and thereby targeting both cancer cells and a key component of the TME innate immune system such as tissue macrophages) hold great potential for the introduction of this multi-faceted oncosuppressor protein in the setting of innovative molecules endowed with the ability to hamper cancer cell growth on multiple levels of action. The gene discussed is RNASET2; the disease is cancer.